R&D Services For Innovation In
Pre-/ Post-/Probiotics, Plant-Extracts & Functional Ingredients
ACARYON's ENVIRONMENT
-
25 years of experience
-
Unique technology platforms
-
Trusted by Global Leaders - Powered by Scientific Excellence
HUMIPLATE: Next Generatrion Microbiome Cultivation Platform
MicroSIS: Development of Next Generation Biotics
ACA-HEALTH: The broadest functional assay platform on the market
Next-Generation ex vivo high throughput microbiome platform with innoculum integrity for true translation.
A full integrated microbiome cultivation platform with demonstrated Inoculum Integrity, with full compositional and function analyses (including all ACA-Health assays) and unique biologically relevant bioinformatic tools for real insights into the mirobiome modulation and health impact of your products
To bridges the gap between preclinical data
and clinical outcomes
To evaluate candidates at different
concentrations, differents conditions and/or
on different microbiomes
To support microbiome safety assessment
25 years of experience and unique MicorSIS platform for the development of next generation biotics
Unique platform allows us to isolate directly out the microbiome, microorganism(s) with target properties: Metabolic properties, functional properties etc.
Specific focus on carbohydrate structures:
Carbohydrates are among the main components on the surface of bacteria. Their application potential is almost unlimited to find pathogens, to stimulate the immune system etc.
Developed one of the first postbiotic with
cancer prophylactic properties
Reaching GRAS Status in the USA and
Novel-Food Status in the EU
Marketing the postbiotic in the EU and the
USA
As a microbiome specialist, ACARYON is also committed to developing innovative solutions for gut-associated diseases, particularly infections for which effective or appropriate treatments are still lacking
Based on its proprietary S-Load Technology, ACARYON develops innovative non-antibiotic solutions for the prevention and treatment of gut infections that currently lack adequate preventive or therapeutic options.
In this effort, ACARYON receives support from the German government, the Berlin region, and the European Union.
